ICCVS biomedical research will directly contribute to clinical benefit in both cancer vaccine development and immunotherapy drug discovery. We lead a program aimed at understanding the biology of antigen presentation, a critical aspect of which is the identification of neoantigens from a landscape of immunopeptidomics studies. These neoantigens serve as candidates for cancer vaccines. Fundamental to the outgrowth of malignant cells is their ability to evade immune elimination. And therefore ICCVS leads a program to understand the mechanisms exploited by cancer, which will inform and guide the development and application of new and existing immunotherapies. Research from both these streams will feed into clinical trials at our partner universities The Medical University of Gdansk and The University of Edinburgh.